Document 0835 DOCN M9480835 TI VIDAS vs ELISA in the serodiagnosis of HIV 1 + 2, rubella and toxoplasma. DT 9410 AU Araj GF; Bizri AR; Fattouh LG; Nassif RE; American Univ. Med. Ctr., Beirut, Lebanon. SO Abstr Gen Meet Am Soc Microbiol. 1994;94:555 (abstract no. C-365). Unique Identifier : AIDSLINE ASM94/94313110 AB Rapid, automated and self-contained instruments that minimize exposure to potentially infectious blood samples are attractive addition to the serodiagnostic laboratory. The performance of Vitek Immuno Diagnostic Assay Systems (VIDAS, biomerieux Vitek Inc., Hazelwood, MO) was tried in a developing country for the detection of antibodies to three infectious diseases. Among 87 selected sera which were tested for anti-HIV 1 + 2, 20 and 13 (of the 20) were positive by ELISA (CLONATEC, Paris, France) and VIDAS, respectively. The Western blot (Lia Tek HIV 1 + 2, Organon Teknika, Boxtel, Holland) done on the 20 positive sera confirmed only the 13 which were also positive by VIDAS. Concordant results were obtained for 21 sera (12 positive) tested for anti-rubella IgG by ELISA (Human, Taunusstein, Germany) and VIDAS. Concerning toxoplasma ELISA (Human), IgM and IgG were positive for 5 of 19 and 27 of 27 sera, respectively, while VIDAS was positive for 1 of 19 and 23 of 27 sera, respectively. An arbitrator Toxo ELISA (Organon) for IgG and IgM confirmed the VIDAS results. The sera with discrepant Human Toxo ELISA IgG & IgM had O.D. readings close to the cut-off values. In addition to the above noted characteristics, the VIDAS is a reliable instrument to introduce in the clinical laboratories performing serodiagnosis of infectious diseases. DE Acquired Immunodeficiency Syndrome/*DIAGNOSIS Antibodies, Protozoan/BLOOD Antibodies, Viral/BLOOD Comparative Study Enzyme-Linked Immunosorbent Assay/*METHODS Human HIV Antibodies/BLOOD HIV-1/*ISOLATION & PURIF HIV-2/*ISOLATION & PURIF IgG/BLOOD IgM/BLOOD Rubella/*DIAGNOSIS Serodiagnosis/*METHODS Toxoplasmosis/*DIAGNOSIS MEETING ABSTRACT SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).